March 6, 2006

Corgentech has reported clinical data from one of two Phase I/II clinical trials of Avrina, the company's NF-kappaB decoy drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema that affects about 52 million adults and children in the U.S., Europe and Japan. Exploratory analysis of efficacy was conducted in this U.S.-based trial to evaluate anti-inflammatory drug effect, and as previously reported in a top-line data announcement last month, the lowest dose evaluated was the most efficacious.

The dose of 0.25 percent almost achieved statistical significance in the analysis of the combined eczema score (designated primary efficacy endpoint) at Day 22, despite the small patient population. A statistically significant reduction in change from baseline for the total symptom score and for the excoriation score was also observed at Day 22 in the 0.25 percent dose group. At two weeks follow-up after drug discontinuation, a pattern of continued efficacy in these parameters and at this lower dose group suggests a potential disease-modifying or skin-healing effect. The primary endpoint of this trial was to establish the safety and tolerability profile of Avrina, and Avrina was shown to be safe and well-tolerated.